• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 4. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

Research Briefing on Benzyl 4-Aminopiperidine-1-Carboxylate (CAS: 120278-07-1) in Chemical Biology and Pharmaceutical Applications

Benzyl 4-aminopiperidine-1-carboxylate (CAS: 120278-07-1) is a key intermediate in the synthesis of various pharmacologically active compounds. Recent studies have highlighted its significance in the development of novel therapeutic agents, particularly in the fields of central nervous system (CNS) disorders, oncology, and infectious diseases. This briefing provides an overview of the latest research advancements involving this compound, focusing on its synthetic utility, biological activity, and potential applications in drug discovery.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the use of benzyl 4-aminopiperidine-1-carboxylate as a building block for the synthesis of selective serotonin reuptake inhibitors (SSRIs). The study demonstrated that derivatives of this compound exhibited high affinity for the serotonin transporter (SERT), with improved pharmacokinetic profiles compared to existing SSRIs. These findings suggest its potential as a scaffold for next-generation antidepressants with fewer side effects.

Another significant application of benzyl 4-aminopiperidine-1-carboxylate was reported in a 2022 Nature Communications article, where it was utilized as a precursor for the development of small-molecule inhibitors targeting protein-protein interactions (PPIs) in cancer cells. The study identified several derivatives that effectively disrupted the interaction between p53 and MDM2, leading to enhanced apoptosis in tumor cells. This research underscores the compound's versatility in oncology drug design.

Recent advancements in synthetic methodologies have also improved the accessibility of benzyl 4-aminopiperidine-1-carboxylate. A 2023 Organic Letters publication described a novel, one-pot synthesis route that significantly increased yield and reduced production costs. This development is particularly relevant for industrial-scale applications, where efficient and cost-effective synthesis is critical.

In the context of infectious diseases, a 2024 study in Antimicrobial Agents and Chemotherapy investigated the compound's derivatives as potential antiviral agents. Preliminary results indicated promising activity against RNA viruses, including SARS-CoV-2 variants, through inhibition of viral replication machinery. While further optimization is needed, these findings open new avenues for antiviral drug development.

The safety profile of benzyl 4-aminopiperidine-1-carboxylate has been extensively evaluated in recent preclinical studies. A 2023 Toxicology Reports article confirmed its low cytotoxicity in human cell lines at therapeutic concentrations, supporting its suitability for further drug development. However, researchers emphasize the need for comprehensive metabolic studies to assess potential long-term effects.

Looking forward, the unique structural features of benzyl 4-aminopiperidine-1-carboxylate continue to inspire innovative drug design strategies. Its piperidine core and versatile functional groups make it an attractive scaffold for medicinal chemistry. Current research efforts are focusing on developing targeted delivery systems to enhance its therapeutic efficacy while minimizing off-target effects.

In conclusion, benzyl 4-aminopiperidine-1-carboxylate (120278-07-1) remains a compound of significant interest in pharmaceutical research. Its applications span multiple therapeutic areas, with recent studies demonstrating its potential in CNS disorders, oncology, and antiviral therapies. Continued research into its derivatives and improved synthetic methods will likely yield novel drug candidates in the coming years.

• 157023-34-2(Benzyl 4-(aminomethyl)piperidine-1-carboxylate)
• 711002-74-3(Benzyl 3-aminopiperidine-1-carboxylate)
• 405057-75-2(Benzyl 4-(methylamino)piperidine-1-carboxylate)
• 109397-72-0(N-Cbz-4,4'-bipiperidine)
• 138163-12-9(benzyl 4-methylidenepiperidine-1-carboxylate)
• 811842-18-9(1-Cbz-2-Aminomethylpiperidine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)